¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/8/10 ¤U¤È 01:30:13
²Ä 618 ½g¦^À³
|
¤µ¤Ñ¤£¥Î«ü±æ¤U¥b½L©Ô©ï¤F¡Aªi¬q¤jP¤wOVER |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/8/9 ¤W¤È 09:33:40
²Ä 617 ½g¦^À³
|
8/3¯dªø¤U¼v½u¡Aµu½u¥i¯à´Nout¡F¦p¯¸Ã26¤¸¥H¤W¡A«hµL®ø®§´N¬O¦n®ø®§¡A´Á«Ý¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/8/4 ¤W¤È 10:28:05
²Ä 616 ½g¦^À³
|
µU¤l¬°¤F¤@®Ú»¿¼¦Ñ¬O³QA¡A¦ý¨Ì½u«¬¬Ý¦n¹³¤S¯d¦³¥ñµ§¡I¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/8/2 ¤U¤È 01:59:29
²Ä 615 ½g¦^À³
|
¦U¦ì¦³¨S¦³µo²{ ´CÅé©ñ§Q¦h ¤½¥q«°T¼á²M ¤j·§´N¬O°ªÂI¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gfun10138468 |
µoªí®É¶¡:2017/7/30 ¤U¤È 10:09:40
²Ä 614 ½g¦^À³
|
¥Í§ÞªÑ³o´X¦~¾ú¸g¸Ñª¼··«B«B¡AµÛ¹ê¥t¤H¤£±Ë»P¼««ã¡C¥»¬O¬ü¨Æ¤@¼Î¡A§Y³yºÖ¤HÃþ¤S¯à¶}³Ð¥xÆW·s²£·~¡C¦ý´CÅéªñ¨Ó¶Ý¦å¦ü¥¼¼f¥ý§P¡AÅý¬ãµo¤Hû»X¨ü·¥¤j¦¾°d»P°d½|¡A¨·Pµh±¤¡C§Æ±æ´CÅé¤Hû¦b³ø¾É¥ô¦ó¨Æ¥ó®É¡A¥ý§@¨¬¥\½Ò¡A¤~¯à¤½¥¿«ÈÆ[¥¿Å³ø¾ÉOBI822Á{§É¤G/¤T´Á¹êÅçµ²ªG©Ò¥Nªí·N§t¡C ¯E¹©µoªí©óASCO½×¤åAbstractŪ«á¤ß±o: a titer ≥ 1:160 &nonresponders:
PFS: HR, 0.52 [95% CI, 0.37-0.71] P< .0001 OS : HR, 0.52 [95% CI, 0.29-0.92] P = .025
Æ[¹îP value< 0.0001 Extremely significant ¡C Globo H¬°¥Ø«e°ß£¸¥uªí²{¦bcancer cell ¤£ªí²{¦b¥¿±`²ÓM¤W¡A¦]¦¹¤£¹³Herceptin·|¤Ö³¡¤À¶Ë®`¨ì¥¿±`²ÓM¡A³Ì¥i¶Q¬OGlobo H vaccine¥i¦P®ÉªvÀø©Ò¦³ER(+),PR(+),HER2,Triple(-)¡C¥Ø«e°ê»Ú¤jÃļtµL¤H¯à¤Î¡C¯f¤H¤£»Ý¹³PD-L1»Ý¨Æ¥ý¿z¿ï¡A¦¹¬Ì]§ÜÅé¥i¿ëÃÑglobe H,¤Îstem cell ¤Wssea 3 and ssea 4¡A³o¤TºØÁÞ¤À¤lGH series§Üì¦bÀù²ÓM¡BÀù·F²ÓM¤W¤À¥¬±µªñ100%¡A©Ò¥H±q¹êÅçµ²ªG±oª¾¡A¥un²£¥Í¦³®Ä§ÜÅétiter ≥ 1:160 ¡A§Y¦³·¥ÅãµÛ©ÊÀøªk¡C
¥Í§ÞªÑ§Y±N§_·¥®õ¨Ó¡A³ß¨ÆÁ{ªù¡C¬u²±ªñ´Á¦¨¥æ¶q«ùÄò©ñ¤j¡A¦b¦b»¡©ú¦³¨Æµo¥Í¡C¬u²±©Î³\¤]±N³¶«Ì¤¤¿ïÀò±o°ê»Ú¤jÃļt«C·ý¡A±ÂÅv¦¨¥\¡C«¥Ì«ø¥Ø¥H«Ý¡C
udn.com/news/story/7254/2612564
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/27 ¤U¤È 01:40:45
²Ä 613 ½g¦^À³
|
¤@ªi¨ì³»¨«¶Õ µ´¤j¦h¼ÆÀ³¸Ó³£¿ù¹L¤F ¦pªG¥¼¨Ó¦³¥D¤É¬qªº¸Ü §Æ±æ¤j®a³£¯à¦³¾÷·|°Ñ»P |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/7/27 ¤U¤È 12:50:33
²Ä 612 ½g¦^À³
|
³QÀ~¨ì¤F¡I¶]¤@¤Uµu½uµL¥i«p«D¡F¦ý¬Ý¤£¥X¤j¤H¦³¯h¾ÎºA¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/26 ¤U¤È 12:29:56
²Ä 611 ½g¦^À³
|
º¦¨ì¤j®a³£¶Ì²´¤F ¤£ª¾¹Dµo¥Í¬Æ»ò¤j®a³£¤£ª¾¹Dªº¨Æ¤F ¤S©Î³\¤°»ò¨Æ³£¨S¦³ ¥u¬O³æ¯Â¥D¤Oª£§@¬°¤F¦Û¤v¸Ñ®M¦Ó¤w |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/26 ¤W¤È 09:14:19
²Ä 610 ½g¦^À³
|
©Ç©Ç!¦³¤HÂP¨ì¬Æ»ò®ø®§¥i§_³zÅS¤@¤U???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/7/24 ¤U¤È 03:47:12
²Ä 609 ½g¦^À³
|
¥H«e³o´X¤Ñ³oºØ¶q¡A¤µ¤Ñ¬u²±¦Ü¤Ö50¤¸¤F¡A¦ý¦]¬°¨ó©M¤jªÑªFÀò§Q¤Fµ²¡]¥xÆW²{¦b¤jªÑªF¯àÁȨì¿ú¡AÀ³¸Ó´N¥u¦³¨ó©M§a¡A¨ä¥L¤£¬O¤W¤£¤F¿³Âd¡A´N¬O³QÂê¡A¯u¬O°ª©Û°Ú¡ã¡^¡A¤£ª¾¹D¥L¤â¤WÁÙ¦³¦h¤Ö¡HY·íªì¬O3ªÑ´«1ªÑ¬Æ¦Ü2ªÑ´«1ªÑ¡A¦Ü¤Ö½æ¶q¨S¨º»ò¤j°Ú¡C
µ²ªG³y¦¨¤µ¤Ñì©l¬u²±ªÑªF¨ü·l¡A¤Wº¦ÁÙ³Q©ì²Ö¡ã
ì©l¬u²±¤pªÑªFªºÅv¯q¦ó¦b°Ú¡ã |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/7/21 ¤U¤È 05:50:16
²Ä 608 ½g¦^À³
|
§Úªº·N«ä¨Ã«D»¡¨ó¦X·sÃĨS¦³»ùÈ¡A¦Ó¬O®Ú¾Ú¤W¦¸ªºªk»¡·|¡A¥¼¨Ó¤T¦~®Ú¥»¨S¦³ÃD§÷¥i¥Hª£§@¡A¦b¥xÆW¡A¥D¤O¥u°µ¦³ÃD§÷ªºªF¦è¡A¤£¬O¦³»ùȪº¡C Y¬Ý»ùÈ¡A¥H«eªº¬u²±¡A¤]À³¸Ón¦³3¦ì¼ÆªºªÑ»ù¡A¬°¦ó¤@ª½¶^¨ì2¢æ¡H´N¬O¦]¬°ÃD§÷¥¼¨ì¡A¥D¤O¤£«æµÛ¶i³õ¡CªO¤WªºªB¤Í¡AÀ³¸Ó¤]µ¥¤F¨â¤T¦~¡A¤µ¦~¤]³\´N§Öµ¥¨ì±ÂÅv¡A²{¦bIµÛ¨ó©M¡A¨ì®É¯uªº±ÂÅv¡AªÑ»ù¸±o°_¨Ó¶Ü¡H ²{¦bÁÙ¤£ª¾¹D³o¥D¤Oªº¤ßºA¬O¦p¦ó¡H¬O¤£¬O¤]¬O¬Ý·Ç±ÂÅv®É¶¡®t¤£¦h¡A¶}©l¶i³õ½ä¤@§â¡A¦ý±ÂÅvY¬OÁÙ¬O»»»»µL´Á¡A¥D¤O¤@°h³õ¡AÁÙ¬O·|¶^¦^°_º¦ÂI....... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/21 ¤U¤È 05:29:17
²Ä 607 ½g¦^À³
|
¤@®a¤½¥qÁÙ¨S¦³·sÃĤW¥«¹s¦¬¤J³ºÈ102»õ¬ü¤¸,Àù¯g·F²ÓM¹Ú¦³¦h¤j! 2016.4¤ëAbbVie¯{¤U¹dÃB¤Ñ»ù102»õ¬ü¤¸¦¬ÁÊStemcentrx¤½¥q©ãª`Àù¯g·F²ÓM Stemcentrx¤½¥q¦³¤Ïú试验©Ê·s药¡A¨ä¤¤¤TÏú¤w¦b¦´Á临§É试验¤¤¨ú±o¤F¥i³ßªº结ªG¡A¥t两Ïú¤]¥¿处¤_I´Á»PII´Á临§É试验阶¬q. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/7/21 ¤U¤È 01:57:11
²Ä 606 ½g¦^À³
|
§ÚÓ¤H§PÂ_¬OÀ³¸Ó¨S¦³¯S§O®ø®§¡A·|º¦ªº²z¥Ñ¡A³æ¯Â¬O¦³¥D¤O¶i¨Ó¡A¥Ø«e¬Ý°_¨Ó¬u²±¥u¬O¨ä¤¤¤@¤ä¡A¦Ó¥L̬Dªº¼Ðªº¡A³£¬O·¥¦³¼ç¤O¡A¦ýªÑ»ù³QÄY«§C¦ô¡A¤µ¤ÑªÑ»ù¤@¤f®ð©Ô¨ì40-50¤]¨SÔ£¦n·N¥~¡A¦]¬°³o¤]ÁÙ¨S¨ì¦X²zªÑ»ù¡C
Y¸s¯qª÷¹©¨º¦ì¤j¤á°±¤î½æ¡AÀ³¸Ó·|©Ô§ó§Ö¡A³o°}¤l¥L¨C¤Ñ½æ50±i¡A¬Q¤Ñ¶X¶Õ½æ186¡A¨S·N¥~¡A¤µ¤ÑÀ³¸Ó·|½æ300±i¥H¤W§a¡C
¦]¬°®õºÖ³Ìªñªº·s»D¡AÅý§Ú·Q¨ì¬°¦ó¨ó©M·sÃĤ£¦Û¤v¤W¿³Âd¡A¦Ó¬O¸ò¬u²±¦X¨Ö¡Aµª®×À³¸Ó´N¬O³oÓ ¡yÃÒ¥æ©Ò26¤é³q¹L®õºÖ-KY¤W¥«¥Ó½Ð®×¡A¨ä¤¤²Ä¤T¶µ¡An¨D¤½¥q¤§¸³¨Æ¡B«ùªÑ¶W¹L¤wµo¦æªÑ¥÷Á`ÃB¦Ê¤À¤§5¤§ªÑªF¡BÁ`¸g²z¤Î¬ãµo¥DºÞ¡A©Ó¿Õ¨ä¨Ì¥»¤½¥q¡u¦³»ùÃÒ¨é¤W¥«¼f¬d·Ç«h¡v²Ä28±ø¤§9²Ä2¶µ³W©w´£¥æ¶°¤¤«OºÞ¤§ªÑ²¼¡AÀ³¦Û¤W¥«¶R½æ¶}©l¤é°_©¡º¡1¦~«á¡A¥B¸Ó¤½¥q¤½§i¥Ó³ø¤§°]°È³ø§iµ|«e·l¯q¬°¥¿¼Æ¡A©l±o»â¦^2¤À¤§1¡A«S±o»â¦^¶°¤¤«OºÞªÑ²¼¶}©l¤é°_©¡º¡1¦~«á©l±o¥þ¼Æ»â¦^¡C¡z ¦pªG·Qn¿³Âd¡A¨S°ÝÃD¡A°ÝÃD¬O¤£¯à½æªÑ²¼¡A¹ï¬Y¨Ç¤jªÑªF¦Ó¨¥¡A¿³Âd´N¨S·N¸q¤F¡A¦Ó¨ó©Mnµ¥¨ì¯àÀò§Q¡A¨S3-5¦~¬O¤£¥i¯àªº¨Æ¡A¥Î¨Öªº°¨¤W´N¥i¥H½æ¡C ¦Ñ¹ê»¡¡A¦X¨Ö§Ú¬O¨S·N¨£¡A¦ý¥Î³o»ù®æ¨Ö¡A®Ú¥»¬OÄ묹¬u²±¤pªÑªFªºÅv¯q
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/21 ¤U¤È 12:39:10
²Ä 605 ½g¦^À³
|
¦³¿c¨ì¤°®ø®§n¤£¤À¨É¤@¤U? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/7/21 ¤W¤È 09:27:49
²Ä 604 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¨Æ10135609 |
µoªí®É¶¡:2017/7/20 ¤U¤È 12:37:18
²Ä 603 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§Ú¨Ó¤F10141579 |
µoªí®É¶¡:2017/7/20 ¤W¤È 08:14:55
²Ä 602 ½g¦^À³
|
¥_·¥20~40 ¦]µØ18~26 §C»ù¥ÍÂåªÑ·|ÃþªÑ½ü°Ê¶Ü¡H ¥H¤W½Ð¤Å°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§Ú¨Ó¤F10141579 |
µoªí®É¶¡:2017/7/19 ¤W¤È 10:50:46
²Ä 601 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/15 ¤W¤È 08:26:17
²Ä 600 ½g¦^À³
|
©³¤UCSCS´£¥X½èºÃªºÃIJz¾÷¨î:...¦ýlong-liveªº¼ß²ÓMFB825¸òQuilizumab±þ¤£±¼¡A³o¨Ç¥i¯àÁÙ¬O·|«ùÄò²£¥Í·|»{¹L±Ó쪺IgE¡A¦Ó¥BÁÙ¦³±qIgG memory BÅܦ¨IgE memory Bªº¸ô®|¡A©Ò¥HIgE¦³¤U°¦ý¯gª¬¨S¦³§ïµ½¡C
¨º»ò¬u²±»P²Ä3²Õ¤H°¨ÁÙ¦P¨B¶}µo§ÜC£`mX¬Ì]»Panti-EMPD¬Ì]? :¥»¤½¥q«Ø¥ß¤§§ÜC£`mXªvÀø¹L±Ó©Ê¯e¯f·sÃħ޳N¥¥x¡A°£¶i¦æAnti-C£`mX ³æ ®è§ÜÅéFB825¶}µo¥~¡A¦P¨B¶}µo§ÜC£`mX¬Ì]¡A¥»¦¸³q¹L¬ü°ê±M§Q¦WºÙ¬°¡uC£`mX peptides for inducing immune responses to human mIgE on B lymphocytes¡v¡A ±M§QÃҮѦr¸¹8,974,794¡C
³o¤@½g2016.7¤ë²Ä4²Õ¹Î¶¤ªF¨Ê²z¬ìµoªí¦bNature Immunology: Autonomous membrane IgE signaling prevents IgE-memory formationµy¨£ºÝÙ. ....Our findings reveal an autonomous mIgE signaling mechanism that normally prevents IgE+ Bmem and LLPC formation http://www.nature.com/ni/journal/v17/n9/full/ni.3508.html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/10 ¤W¤È 11:45:01
²Ä 599 ½g¦^À³
|
¤d½u¸U½u¤£¦p³o¤@±ø½u! ñ´»CDA¦³¨S¦³Ã¹¤ó»P¿ÕµØ??? §äµo¨¥¤H¥H³Ì¦Ã±¸pªºG®a....ÂPÂP¬Ý!
Xolair¥Ñù¤óRoche(¬ü°ê¥«³õ...)©M¿ÕµØNovartis(¼Ú¬w¥«³õ)Áp¦X¾P°â. ªñ¦~xolair±M§Q³°Äò¨ì´Á,ù¤ó©M¿ÕµØn·Q¤è³]ªk¾d©T®ð³ÝëC³Â¯l¥«³õ,¦]¦¹QuilizumabÁ{§É®É·í¥H®ð³ÝëC³Â¯l¬°Àu¥ý. Y2®a³£¦³Ã±CDA,¨º»ò²Õ¦XÀøªkFB825+ xolair´N¬O¤@¿ï¶µ,°£¤FÀ±¸Éxolair¦]Ige¤ô¥»PÅ髪º¨î±ø¥ó¦ÓµLªk¬I¥´ªº±wªÌ. ¤]¯à¹ïXolair¥Íª«¬Û¦üÃħΦ¨«Ì»Ù.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/10 ¤W¤È 08:59:45
²Ä 598 ½g¦^À³
|
¨S¿ù,Á{§É¥¼¤½¥¬«e,½Ö³£»¡¤£·Ç ©êºp,¤Ö¥´¤@¦r¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/10 ¤W¤È 08:54:20
²Ä 597 ½g¦^À³
|
¨S¿ù,Á{§É¥¼¤½¥¬«e,½Ö³£»¡·Ç ¬O§_³]©wªº°Ñ¼Æ,±ø¥ó·|¼vÅTµ²ªG? ´N¦³½ÐC¸òR¤j¸ò¤j®a¸ÑªR¸ÑªR ¦]¤W¦¸¤½¥q¦³´£¨ì,ù¤ó³]©wªº¤£¬O«Ü¦n
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/7/9 ¤U¤È 08:59:55
²Ä 596 ½g¦^À³
|
¬JµM³£¤w¸g³Q®M¤F¡A·Q¶}¤@ÂI§_«hÅåÀ~°h³õ¤£´NÁ«¤j¤F¡C ¥Í§Þ§Ú¬Oªù¥~º~¡A¦ý´¶Ã¹¤j²³¦³½Ö¨º»ò¼F®`¥i¥H»¡±o·ÇÁÙ¤£¬O¸ÕµÛ°µ¨«µÛÁ@¡A§ó¦óªp§ÚÌÁÙ¦³¤¤¬ã°|¡B¥x¤j¡B¡Bµ¥±M·~»â°ì¹Ù¦ñ¥B¦³¶°¹Î§ë«H©Mª¾¦W¤j©@¬Û¦ñÀH¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/7 ¤U¤È 11:46:06
²Ä 595 ½g¦^À³
|
¨ó©Mªº¸~½F·F²ÓM°ö¾i·f°t¬u²±ªº¥þ¤H§ÜÅé®w¥¥x¿z¿ï¥X§ÜÅéÔ¿ïÃĪ« ³o¤G®a¤£¨ã¦³¤¬¸É©Ê? ¦b¦P¤@®a¤½¥qªºû¤u·|·d¬£¨t°«ª§,¦óªp¬O¤£¦P®aû¤u?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/7 ¤U¤È 11:40:27
²Ä 594 ½g¦^À³
|
¯u¦³³o»òÁV¿|! ·R´þÀù¯g¯à¦³²Õ¦XÀøªk,¦Û¨§K¬Ì¯e¯f´N¦æ¤£³q? Ige¤ô¥¶W¹L¨î¤£¯à¬I¥´? ¤½¥qºô¶©ú¸üFB825©MXolair(©ÎFB317)¦X¥Î¡Aµo´§¬Û¼¥\®Ä¡A¨Ã´î§CXolairªº¥Î¶q¡A¤Î°§C¹L±Ó±wªÌ»PÂåÀø¨t²Îªº¸gÀÙt¾á 6/30°ê®õªk»¡·|²³ø¤¤««×¹L±Ó©Ê®ð³Ý¤´¦CªvÀø¾AÀ³¯g,¦bP2aµ²ªG¥X¨Ó©ÎFB317®³¨ìÃÄÃÒÀ³¸Ó´N·|Á{§É²Õ¦XÀøªk? Anti-M1¡¦ / Anti-C£`mX/ anti-EMPD ¦U¦ÛºÙ¸¹. 2017¦~²Ä3²Õ¤Hªº³ø§i: ¡K. Based on our in vitro findings, we propose that Ce3 targeting could be combined with EMPD targeting to further exploit possible additive effects similar to what was observed with our in vitro combinations ( Fig. 2C). Our observation might spur future clinical modalities, including established anti-IgE therapies. As an example, the obvious group of allergic asthma patients that are currently not eligible to Omalizumab therapy due to excessive IgE levels and/or body weight ( Cohen et al., 2014 ; Liour et al., 2016) might benefit from such combined anti-IgE therapies involving soluble IgE targeting and human EMPD IgE targeting http://www.sciencedirect.com/science/article/pii/S0022175917300650
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/7/7 ¤U¤È 09:49:31
²Ä 593 ½g¦^À³
|
¹ï©ó¦¹¦X¨Ö®×¥uı±o¬O¾Þ§@¡A¦P¶°¹Îªº¤½¥q¦³»Ýn¦X¨Ö? ¤j·§¬O¨ó©M¿³Âd«ÜÃø¡A¨Ö¦¨¬u²±ªÑ²¼´N¯à½æ¤F¡A ¤S¦h¤@°ïªÑ²¼¯à½æ¿ú¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/7/7 ¤U¤È 09:37:10
²Ä 592 ½g¦^À³
|
ªÑÅv¶W¹L¤@¥bªº¥x¤j¡B¤¤¬ã°|¤Î½²¦ÑÁó¤S¦p¦ó·|¦P·N¦¹¤@¦X¨Ö®× |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/7/7 ¤U¤È 09:31:49
²Ä 591 ½g¦^À³
|
·PÁÂcscs¤jªá®É¶¡¤Q¤À¸ÔºÉ¦a¸Ñ»¡¡A¯Â¬ì¾Ç²z©ÊÀËÅç ÃĪ«§@¥Î¾÷¨î¡A¤W¤FÄ_¶Qªº¤@½Ò¡A´CÅé¤@¸ô³ø³ß¤£³ø ¼~¡AªÑ»ù¤Ï¬M¤@®a¤½¥qªº»ùÈ¡A¦A¶Ìªº¤H¤]µoı¤£¹ï ¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/7 ¤U¤È 09:23:29
²Ä 590 ½g¦^À³
|
¥i¯à¤½¥q¤]·NÃѨì¤F ©Ò¥HÂX¤j¾AÀ³¯g,¥Ó½Ð©t¨àÃÄ ¬°FB825¥t´M¥X¸ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/7/7 ¤U¤È 08:56:52
²Ä 589 ½g¦^À³
|
¦p¦¹¤£´N³´¤JªdÕ襤¡A¦ý¤G¦~«eÂà¨ü4¸U¦h±iªº©@¤£¤]¬O«ÜÁV¿|¶Ü¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/7/7 ¤U¤È 05:51:53
²Ä 588 ½g¦^À³
|
Roger¶Kªº¤å³¹·Q»¡Åý§A¸ÑÄÀµ¹¤j®a¬Ý¡A§Ú´N¤£¥Î¥´¤@°ï¦r¤F¡A ´N¬ì¾Ç¤W¨Ó±´°Q¡A§Ú¬O½Ö¨Ã¤£¼vÅT§ÜÅ骺§@¥Î¾÷¨î¡C
¤ÞzAnti-IgEÃĪ«ªvÀø¡uºC©ÊëC³Â¯l¡vªº¾÷¨î±´°Q¸Ìªº¤º®e¡A °ò¥»¤W¡A¤j³¡¥÷ªº¹L±Ó²{¶H¡A³£¨Ó¦Û¤HÅ餺ªº§K¬Ì²ÓMIgE¤À¤l¡C¦b¸ûì©lªºÀô¹Ò¸Ì¡A¦]¬°¦³³\¦hªº±H¥ÍÂε¥·P¬Vª«¡AIgE¤§©Ò¥H
¦s¦bªº¥Dn§@¥Î¡A´N¦b©ó¥D§ð³o¨Ç¯fìÅé¡C·í·P¬Vµo¥Í®É¡AIgE·|¶}©l¤j¶qªº¥X°Ê¡A¶e¨ì³o¨Ç¥~«Iª«¡A¨Ã¥B©M¥Ö½§¼h¤ºªº¡u¥¨¤j
²ÓM¡v(mast cells)¤Wªº¨üÅéµ²¦X¡C
¥¨¤j²ÓM¬O¤HÅé²£¥Íµoª¢¤ÏÀ³ªº¥Dn¨¤¦â¡A¦h¦s¦b©ó¥Ö½§¼h¡A·íIgE©Ô¨ì¥~¨Ó·P¬Vª«ªº§Üì(antigen)¸g¥Ñ©M¥¨¤j²ÓMªº¨üÅé
(receptor)¡AºÙ¤§ Fc£`RI¡A²£¥Í±µÄ²«á¡A¥¨¤j²ÓM´N¶}©l¬¡¤Æ¡A¦b§Üì¥æ¤e³s±µ«á(Crosslink)¡A¥¨¤j²ÓM¶}©l¬¡¤Æ¡A²£¥Í¦UºØ
Äè¼Äª«½è¡A¥]¬A²Õ´Ói¡B¨x¯Àµ¥¡A·í¥¨¤j²ÓM±N³o¨Çª«½èÄÀ©ñ¥X¨Ó®É¡A¤]´N¬O¬°¤°»ò§Ų́Å馳µoª¢²{¶Hªºì¦]¡C¦¹¥~¡A¶ÝÆP©Ê
²ÓM¡A¬O©M¥¨¤j²ÓM©Ê½è¬Û¦üªº§@¥Î¡A¤]¦³Fc£`RI¨üÅé¡A¥u¤£¹L¥¦¬O¦b¦å²G¤º¬y°Êªº¡C
¹L±Ó²{¶H¥ÑIgE©Ò³y¦¨¡A´î¤ÖÅ餺IgEªº¶q´N¯à¦³®Ä´î½w¯gª¬¡Aomalizumab¯à³o»ò¦³®Ä´N¬O¥¦¯à¨³³tªº¤¤©M¦å²G¸ÌªºIgE¡A Åý³o¨ÇIgE¤£·|¦A¸ò¨üÅéµ²¦X¡A¤£·|¦A«ùÄòªº²£¥Í¹L±Ó¤ÏÀ³¡C ¤¤©M¤§«áÅ餺ÁÙ¬O·|Ä~Äò¥Í¦¨IgE¡A©Ò¥Hn2~4¶gÄ~Äòª`®g¡A¤~¯à±±¨î¯f±¡¡C ·íÅ餺IgE¤Ó°ª®É¡AomalizumabµLªk§¹¥þ¤¤©M¦å²G¸ÌªºIgE¡A¦]¬°¤~·|³]©w¨Ï¥Î½d³ò30~1300IU/mL¡A ¶W¹L1300IUªº¯f±w¤£·|¨Ï¥Îomalizumab¡A AD¯f¤HªºIgE¦³¨Ç³£«D±`°ª¡A¬Æ¦Ü¨ì¤W¸U¡A¥Îomalizumab¬°¦ó¦³®Ä?±À´úªº¾÷¨î¥i¯à¬OIgE:omalizumab immune complexes¡A ³o¨ÇIgE-omalizumabµ²¦Xª«¦bÁÙ¦b¥NÁ±¼¤§«e¡A¦bÅ餺¦³¹³¹L±Óì²M°£¾¯ªº¥\¯à¡A ¦]¬°¹L±Óì³QIgEµ²¦X¤F¡A¦ý¤S¤£¯à¸ò¨üÅéµ²¦X¡A©Ò¥H¤£·|¤Þ°_¹L±Ó¤ÏÀ³¡A ·íµM³o¬O±À´úªº¡A«Ý½T»{¡C
FB825¸òQuilizumab³£¬O°w¹ïC£`mX¡A¤]ºÙ§@M1¡¦ªº°Ï°ì¡A³o¬O¦b½¤«¬IgE B²ÓM¤Wªº¤@Ó°Ï°ì¡A¦å²G¸Ìªº¤Àªc¥X¨ÓªºIgE´N¨S¦³³o
¤@³¡¤À¡C
oncohemakey.com/biology-of-the-b-lymphocyte/ ¬Ý¹Ï8.1 ¦¹¬°B²ÓM¤À¤Æªº¹Lµ{¡AB²ÓM¦¨¼ô¨ì³Ì«áÅܦ¨¼ß²ÓM(plasma cell)¡A¼ß²ÓM¬OÅ餺¥Í¦¨§ÜÅ骺²ÓM. ¤À¤Æ¨ìmemory Bªº®ÉÔ¡A²ÓMªí±ÁÙ¦³½¤«¬ªºIg, ¦pIgA, IgG, IgE, FB825¸òQuilizumab°w¹ïªº³£¬O±a¦³½¤«¬IgEªºB²ÓM¡A©Ò¥H±þ±¼±a¦³½¤«¬IgEªºmemory B¤§«á´N¤£·|¥Í¦¨IgE¼ß²ÓM¡A¶i¦Ó´î¤ÖIgEªº¥Í¦¨¡C
¤@¼Ë¬O´î¤ÖIgE¦ý¾÷¨î¬O¤£¦Pªº¡A¦b¯S©wIgE¿@«×¤Uomalizumab¥i¥H§â즳ªºIgE³£²M°£±¼¡A¦pªG¬O«D±`°ªIgEªº¡A ¥i¯à¤]¦³immune complexesªºÀ°§U¯à²M°£¹L±Óì¡A¦]¦¹¯gª¬¦³§ïµ½¡C FB825¸òQuilizumab¯àªý¤î·s¥Í¦¨IgEªº¸ô®|¡A¦ýÅ餺즳ªºIgE¨Ã¤£·|²M°£¡A ³¡¤À²£¥ÍIgEªº¨Ó·½³Qªý¤î¤F¡A¦ý즳ªºIgEÁÙ¬O¦³¯à³y¦¨¹L±Ó²{¶Hªº¼Æ¶q¡A ¼ß²ÓM¦³long-live»Pshort-live 2ºØ¡Aµu©Rªº·íµM¤ñ¸û§Ö¦º±¼¡A«áÄò¤£¼vÅT¡A ¦ýlong-liveªº¼ß²ÓMFB825¸òQuilizumab±þ¤£±¼¡A³o¨Ç¥i¯àÁÙ¬O·|«ùÄò²£¥Í·|»{¹L±Ó쪺IgE¡A ¦Ó¥BÁÙ¦³±qIgG memory BÅܦ¨IgE memory Bªº¸ô®|¡A©Ò¥HIgE¦³¤U°¦ý¯gª¬¨S¦³§ïµ½¡C IgE¦³»{¹L±Óì»P¤£»{¹L±Ó쪺¡A·|»{¹L±Ó쪺IgE¥i¯à¦û¥þÅéIgEªº´X%¦Ó¤w¡A¦ý³o´X%ªºIgE´N¯à³y¦¨¹L±Ó¯e¯f¡C OmalizumabÁöµM¤]±þ¤£±¼long-live IgE¼ß²ÓM¡A¦ý¥¦¯à¨³³t¦³®Ä°§C¦å²G¤¤ªºIgE¡A´N¬O¦³®Ä¡C
FB825®ÄªG¤ñ¸û¦n?¥u¾a¤½¥qªº§ë¼v¤ù¬O¬Ý¤£¥X¯uªºµ²ªG¡ARoche°µ§¹Á{§É³£µopaper¸Ô²Ó»¡©ú¡A FB825ªºµ²ªG¦bþ?¦³´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü¡A§Ú¼gªºªF¦è¤£·|Åý§A·Q¶RªÑ²¼¡A¤£·|Åý§A½ß¿ú¡A §Ú¤]»¡¤F¡A¤G´Áµ²ªG¥X¨Ó¦A»¡¡A¤Ó¦»¡¦³¦h¦n¦h¦n³£¬OªÅ½Í¡A ²³¦h®ø®§¸ÌÁÙ¬On²z©Êªº§PÂ_¤ÀªR¡A¦³¨Ç¤H¨S¦³¬ÛÃöI´º¡A µLªk¤ñ¸û¸Ô²Óªº¤F¸ÑÃIJz¾÷¨î¡A¥ú¾a®ø®§±¨Ó¨M©w¡A¹ê¦b¬O¥Rº¡·ÀI¡A ÁöµM»¡°ª·ÀI°ª³ø¹S¡A¦Û¤v²z¸Ñ§¹¨M©w¦Û¤vªº§ë¸ê¡A¦p¦¹¦Ó¤w¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/7 ¤U¤È 12:38:08
²Ä 587 ½g¦^À³
|
·Q·Q¤]¬O!´Nºâñ´»CDA¦³¥]§tù¤ó, ¥H¦ûÀù¯gÃĪ«¥«³õ³Ì¤jÀYªºÃ¹¤ó,»¡¤£©w¦³¿³½ì¬Û¤¤ªº¬O¬u²±¿W¨B¥þ²y¤§¸~½F·F²ÓM°ö¾i¡B·sÃÄ¿z¿ï¥¥x |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/7 ¤U¤È 12:14:09
²Ä 586 ½g¦^À³
|
©Î³\¤j®a·Qªº¥i¯à³£¬Û¦ü. ù¤ó2´Á°µ§¹¤£°µ¤F ¬O§_·|ª½±µ¨ÓÃöª`®ÄªG¸û¦nªºFB825 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/7/7 ¤W¤È 11:35:47
²Ä 585 ½g¦^À³
|
§O¦h¦¹¤@Á| ¬J¬O«O±K¨óij¦ÛµM¥]§tñ¬ù¹ï¶H «ç¥i¯à¦^µª§A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/7 ¤W¤È 11:35:07
²Ä 584 ½g¦^À³
|
ROGER¤j: ¦³Ãø«×°Ú,ªB¤Íªº¦P¾Ç¥h¦~¤U¥b¦~¤wÂ÷¶}¤F¦¹¤½¥q
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/7 ¤W¤È 11:29:57
²Ä 583 ½g¦^À³
|
¾Ö¤j: ³Ò±z¦V¤½¥q±´¸ß©³¤U·s»D¨Æ¥óñ´»CDA¦³¥]§tù¤ó? ¦³«h§ó¥¿±¼ÖÆ[
2017-01-12 01:10¸gÀÙ¤é³ø ¤p¼¯¥ÍÂå¦~·|¡A¥x¼t¨ü«C·ý¡C¥x¼t°Ñ¥[¼¯®Ú¤j³q°ê»Ú¥ÍÂå¦~·|¡]J.P. Morgan Healthcare Conference¡^¶Ç¨Ó³ß°T¡A¥]¬Aù¤ó¡B¼b¥Í¡B§¨Ó¡B¿ÕµØµ¥°ê»Ú¤@½u¤j¼t¶}¥X±ø¥ó¡A±N§ÞÂà¥x¼t§ÜÅéÃIJ£«~¡A¨ä¤¤¬u²±¡B¦X¤@µ¥¤½¥qªº²£«~§Þ³N¸ß°Ý«×°ª
«á¨Ó¤½¥q¼á²M»¡©ú:¥»¤½¥q¤w»P¦h®aÃļtñ´»CDA¡A¬ÛÃö¨Æ©y§¡¶·¿í¦u«O±K¨óij |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/7 ¤W¤È 10:52:57
²Ä 582 ½g¦^À³
|
XolairÀòFDA®Ö㪺2ºØªvÀø¯e¯f:®ð³Ý/ºC©ÊëC³Â¯l
1.Anti-IgEÃĪ«ªvÀø¡uºC©ÊëC³Â¯l¡vªº¾÷¨î±´°Q Xolair ªº§@¥Î¦b©ó¤¤©M¤HÅ餺ªº§K¬Ì§ÜÅéIgE¡C¾ãÓ¥Ö½§¾Ç»PÁ{§É§K¬Ì¾Ç¬É¹ïXolair¬°¦ó¯àªvÀøCSU¡uºC©ÊëC³Â¯l¡v·P¨ì¤£¸Ñ¡Chttp://www.genomics.sinica.edu.tw/index.php/tw/news/news-archives/429-anti-ige
2.http://www.e-jmii.com/article/S1684-1182(11)00267-2/pdf ......IgE levels and eosinophil percentages are not good indicators for a prolonged course of urticaria(ºC©ÊëC³Â¯l). (AD±wªÌ»PIgE levels°ª«×¦³Ãö) http://www.e-jmii.com/article/S1684-1182(11)00267-2/pdf |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/7 ¤W¤È 10:25:00
²Ä 581 ½g¦^À³
|
Xolair¤W¥«¾P°â§Ö15¦~©|¦³ÃĪ«¾÷¨îIgE:omalizumab immune complexes«Ý½T»{! FB825»PQuilizumabªºÃĪ«¾÷¨î±z¤w§¹¥þºN²M? «¥µù¥U½s¸¹¡G10144700,±z¦«¥´X¸¹. ±zªº¨¤À¤£¥~3ºØ¥i¯à©Ê:¬u²±Â÷¾û¤u/¥Ñ·RÂà«ë¦a§ë¸ê¤H/¨ä¥L? ¦pªG¬u²±¦b¦¨Ç¦~ªº¤¤°ª»ù¦ì,±zªº¨¥½×«¥¯à»{¦P! ¦Ó©Ò¶Kªº¬ã¨s³ø§i¦®¦bªí¹FAD¤¤««×±wªÌ(extrinsic¥~¦]©Ê)»P°ªIge¤ô¥¤GªÌ¶¡ªºÃö³s©Ê¤ñQuilizumabÁ{§ÉªºAllergic asthma; Allergic rhinitis; Urticaria¶¡§ó©úÅã!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/7/7 ¤W¤È 09:03:54
²Ä 580 ½g¦^À³
|
R¤jn¤£n¸ÑÄÀ¤@¤U2012¨º½gpaper¡A»¡©ú¬°¦ó¶W°ªIgEªºAD¯f¤H¨Ï¥Îomalizumab¡A §Y«KµLªk§¹¥þ¤¤©MIgE«oÁÙ¬O¦³¯f±w¦³§ïµ½? OmalizumabªºÃIJz¾÷¨î¸òFB825ªº¤£¦P¦bþ?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/6 ¤U¤È 03:40:53
²Ä 579 ½g¦^À³
|
ROGER¤j: ¬Ý±o¥X¨Ó,§A¹ïFB825«Ü¦³«H¤ß ·sÃij̫á¯à¦¨¥\ªº¯uªº¤£¦h ¤]§Æ±æ¤½¥q¤£nÅý§ë¸ê¤H¥¢±æ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/6 ¤U¤È 02:27:54
²Ä 578 ½g¦^À³
|
FB825¦bÁ{§ÉP1¥´1°w°40~50% ;¥xÆWÁ{§ÉP2a¥´3°w! ³Ì«á´£¨Ñ¤G½g³ø§i¼fµøAD±wªÌtotal Ige°40~50%¯gª¬·|¤£·|§ïµ½? ¥t¥~¥þ²y¿W¨B±M§Q¤§¸~½F·F²ÓM°ö¾i»P¿z¿ï¥¥x·|¤£·|¤Þ°_°ê»Ú¤jÃļtª`·N? 1. 2012¦~±i¤l¤å Among patients with atopic dermatitis, the proportion with IgE above 700 IU/mL is much larger than that for adult allergic asthma: it is common to find atopic dermatitis patients with serum IgE even higher than 10,000 IU/mL.....dermatitis, the IgE levels are too high to be neutralized by affordable doses of omalizumab. (¥xÆW¹L±Ó®ð³Ý±wªÌallergic asthma¥´1°womalizumab¬ùNT$15000) http://www.sciencedirect.com/science/article/pii/S102781171200095X
2.·Ó¤ù²³æ©öÀ´! 2017 April ¹ÏA /B total Ige±q17,183 IU/mL°¨ì11,983 IU/mL(¬ù°30%). http://www.mdedge.com/cutis/article/136166/atopic-dermatitis/severe-refractory-atopic-dermatitis-elevated-serum-ige |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/6 ¤W¤È 09:03:04
²Ä 577 ½g¦^À³
|
±q2016¦~1¤ë¦Ü¤µ¦@1¦~¥b®É¶¡ùØ «ù¦³1000±i¥H¤W¤jªÑªF±q¥¼¦³°Ê§@ ¤W©P¬ðµM¼W¥[7¦Ê¦h±i ³o......... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/5 ¤U¤È 08:51:21
²Ä 576 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/5 ¤U¤È 07:50:19
²Ä 575 ½g¦^À³
|
cscs¤j:·Pı§A¬O¥Í§Þ°é¤º¤H ¬Ý¨ÓªÑ»ùªu¸ô¯}©³ªºì¦] ¬O¦¦³¤Hª¾¹DFB825¦¨¥\¾÷²v§C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/7/5 ¤U¤È 06:36:30
²Ä 574 ½g¦^À³
|
¬Ý§¹cscs¤jªº¸ÑÄÀ ¤~ª¾¹D¦Û¤v¤Ó¹à¤F ¬Ý³ø¯Èª±ªÑ²¼ «ç»ò¦ºªº³£¤£ª¾¹D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/7/5 ¤U¤È 05:10:02
²Ä 573 ½g¦^À³
|
MEDI4212µ²¦XIgEªº¿Ë©M¤OÁöµM°ª¡A¦ý¥¦¸ÑÂ÷ªº³t«×¤ñXOLAIRÁÙ§Ö¡A ³y¦¨¦å²G¸ÌIgE¿@«×¦^´_ªº³t«×¤ñXOLAIRÁÙ§Ö¡A¬Û¸û¤§¤U´N¤ñ¤£¹LXOLAIR¡C
UB221»PCD23¤W±ªºIgE§@¥Î¡A¬O§_¯à§ó¥[´î¤ÖIgEªº¥Í¦¨¡A¯uªº¨S°µÁ{§É¤£ª¾¹D¡A «ù¥¬Ý«Ý§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/5 ¤U¤È 04:39:49
²Ä 572 ½g¦^À³
|
¹L»P¤£¤Î¡A¬Ò¦³¥¢¤§¡A¨D¤¤±e¡C
UB-221¨ã¦³¤£¦P©óXolair®ªº§@¥Î¾÷¨î¡A°£¤F¥i¥H¤¤©M¤Þµo¹L±Ó¤ÏÀ³ªº¥Dn¤À¤lIgE¡A¤]¥i³z¹L»P(CD23)¨üÅé¤WªºIgEµ²¦X®ÄÀ³ MedImmuneªºmedi4212¤¤©MIge±j©óXOLAIR 10¿¤S¦p¦ó? SAE¹L¤£¤FÃö´N¬O¥¢±Ñ¦¬³õ,«öC¤jªº±À²zì«h UB-221¤]¤£®e¼ÖÆ[???
MEDI4212 potently inhibited responses through Fc£`RI and also prevented the binding of IgE to CD23. When used ex vivo at identical concentration, MEDI4212 depleted free-IgE from human sera to levels ~1 log lower than omalizumab https://kclpure.kcl.ac.uk/portal/en/publications/a-novel-igeneutralizing-antibody-for-the-treatment-of-severe-uncontrolled-asthma(19cb9e9d-0e97-4b72-bfc7-6fcd88f4f1ef).html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/7/5 ¤U¤È 01:13:13
²Ä 571 ½g¦^À³
|
¨Ó¦^ÂФ@¤UFB825»PUB221¡A ¬u²±±ÂÅvFB825®É¡AUB221ÁÙ¨S°µ¦n¡A FB825¦³¿W¯S©Ê¡A°£¤FROCHE¨S¦³¨ä¥¦¤H¦³¡A UB221±«e¦³XOLAIR³o®y¤j¤sÀY¡An¶W¶V¥¦¤£¬O³o»ò®e©ö¡A ¦Ó¥BÁÙ¦³¨ä¥¦Ävª§ªÌ¤]¦b±Æ¶¤¤F¡C UB221»PXOLAIR³£¬O°w¹ïfree IgE¡A ÁöµMUB221ÁÙ¦³¤£¦Pªº¯S©Ê¡A¦¹¯S©Ê¦³¥i¯à¥h°§CIgEªº¥Í¦¨¡A ·íµM³o¥u¬O²z½×¤W¡A¹ê»Ú¤W·|¤£·|¤ñXOLAIR±j¡A³oÓ¤j·§n§¹¦¨Á{§É¤~¯à±o¨ìµª®×¤F¡C Áp¥ÍÃĦ³¿³½ì·íµM´N§ÞÂà¡A¦pªG¨S¤H¦³¿³½ì´N¥u¬O©ñµÛ¡A¤£·|¦Û¤vµo®i¡C
FB825ªº½T¤]¦p¹w´Á¯à±þ±¼½¤«¬IgEªºB²ÓM¡A¶i¦Ó´î¤Ö²£¥ÍIgE¡A ¦ý¦³¨Ç¬¡«Ü¤[ªºIgE¼ß²ÓM·|¤@ª½²£¥ÍIgE¡A¦å²G¤¤ªºIgE¤U°¤FÁÙ¬O¤£ºâ§C¡C ¦bIgE¤£¬O«Ü°ªªº¯f±w¨Ó»¡¡A¨Ï¥ÎXolair¥i¥H°¨¤W°§C¦å²G¤¤ªºIgE¡A ÁöµMn«ùÄò¬I¥´¡A¦]¬°¯à¦³®Äªº²M°£IgE¡A©Ò¥H¯gª¬¯à±o¨ì§ïµ½¡C
FB825n°w¹ï°ªIgEªº¯f±w¡A°²³]¬O1500IU¥H¤W¡A´î¤Ö50%ÁÙ¬O¦³750IU¡A Å餺³oºØ¿@«×ªºIgE¥i¯àÁÙ¬OÅý¯gª¬«ùÄò¡A¨Ã¨S¦³§ïµ½¡A ¦óªp¦³¨Ç¯f¤HªºIgE¬O§ó°ªªº¡A³æ¾a³o¼Ë´Nn¦³Àø®Ä¬O¤£¬O¨º»ò®e©ö¡A
¾Ö¤j¡A respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0347-2 Quilizumab¦b¤ñ¸ûÄY«ªº®ð³Ý¤¤¨Ã¨S¦³±o¨ìÀø®Ä¡AFB825¤]¤£·|¥h°µ³o¼Ëªº¹Á¸Õ¡A ©Ò¥H¥u·|¬D¨ä¥¦¾AÀ³¯g¡A©Î¬On¥h¥Ó½Ð©t¨àÃÄ¡A¨ä¥¦¾AÀ³¯g¤£¤@©w¦³®Ä¡A©t¨àÃĤ@¦~ªº¥«³õ¨Ã¤£¤j¡A¦Ó¥B°w¹ï°ªIgE¯f±wÁÙ¬O¹J¨ì¦P¼Ëªº°ÝÃD¡C
¥²³Ó¤j¡A ²q´ú¤£¬O½Í±ÂÅv¤~©ì©µÁ{§É®Éµ{¡A¦ÂI°µ§¹Á{§É¤~¯à¦ÂI¥X°â¡A «e´£¬On¦³®Ä¡A¬Ý¨ìRocheªºµ²ªGÀ³¸ÓÅý¬u²±¦b¦Ò¼{n¤£n°µ¤U¥h¤~ºC¤F¸}¨B¡A °Ñ¦ÒRocheªºqulizumab¤ñ¸û±µªñFB825ªºÃIJz¾÷¨î¡C quilizumab¤£Ä~Äò¤F¡AFB825ÀY³£¬~¤F¤]¥u¯àÄ~Äò¤U¥h¡A ¤@¨Ó¬O¨S°µ¨ì³Ì«á·íµM¤£ª¾¹Dµ²ªG·|¦p¦ó¡A¤G¨Ó¬O²{¦b°±¤F´N¬O»{¿é¡A ¤]¨S¦³¸ÜÃD¥iª£¡A©Ò¥H¤G´ÁÁÙ¬OnÄ~Äò°µ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/5 ¤U¤È 12:25:41
²Ä 570 ½g¦^À³
|
2´Á¹L¤F¦A¨Ó½Í±ÂÅv,»ù½X¤~·|¤ñ¸û¦n ¤~¤@´Á¹L¤F¤½¥q´N«æµÛ±ÂÅv ®ö¶O§Ö1¦~ªº®É¶¡
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/7/5 ¤W¤È 11:47:53
²Ä 569 ½g¦^À³
|
¾Ö¤j ®ð³Ý¯f¥ÎÃÄÄvª§¤Ó¿E¯P¡A§äÄvª§¸û¤ÖªºÂÅ®üÀ³¸Ó¬O¤½¥qªº µ¦²¤¡A§Úªº¬ÝªkFB825©Î³\¦³½Í±ÂÅv¦]¦¹©ì©µÁ{§É®Éµ{¡A ¥i¯à¬O³Ì«á¨S½Í¦¨¡A²{¦b¤~¶}©l°µÁ{§É¡A¤£¹LºCÁ`¤ñ¥¢±Ñ ¦n¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/5 ¤W¤È 10:05:54
²Ä 568 ½g¦^À³
|
¤µ¤é®ø®§è¬Ý¨ì: FDA©Ó诺¡G9¤ë21¤é«e¸Ñ决©Ò¦³积压ªº©t¤I药¥Ó请¡I http://www.biodiscover.com/news/politics/724261.html
¥HFB825·|¦b2017.12.31¤é«e°e¥X¥Ó½Ð¨Ó¬Ý«Ý¸û§´·í! ·|¤£·|¦³´£¦¤§³ß,«¥¤£ª¾! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/5 ¤W¤È 09:57:16
²Ä 567 ½g¦^À³
|
§ä¥X¸ûµu¤S§Ö¦a¦¨¥\¸ô®|¥dnºò! ³o¬O¥h¦~ªÑªF·|«á: [·|û¡G¤p½Þ10138068 µoªí®É¶¡:2016/6/15 ¤W¤È 10:36:38 ²Ä 169 ½g¦^À³ ¤µ¤Ñ°Ñ¥[ªÑªF·|¡AÃø±o¤½¥q«H¤ßº¡º¡ «ÂI¤@¡G¢Ô¢Ð825±ÂÅvª÷¤w¸g¤£·|¬O´X¦~«e¹w¦ôªº¤»õ¬üª÷¡A¥«³õ¤wÅܤj¡A©Ò¥H±ÂÅvª÷·|§ó°ª¡C]
³o¨Ç¬O2¦~¤ºÃĬɱÂÅv¨ÖÁʮת÷ÃB: 1.ZiarcoªºZPL389¦bP2aÁ{§É¤½¥¬«á³Q¿ÕµØ¥H10»õ¬ü¤¸¦¬ÁÊ¡C 2.ªü´µ§Q±d±N2´Ú¥Ö½§¯f¸ê²£§@»ù10»õ¥X°âµ¹LEO Pharma(+1.15»õ¬ü¤¸ªº¹w¥I´Ú=Á`»ù11.15»õ¬ü¤¸) 3.½÷·ç52»õ¬ü¤¸§¹¦¨¦¬ÁÊAnacor¡AÀò±o¼ç¦b«½SÃĪ«crisaborole»´«×¦Ü¤¤«×¹L±Ó©Ê¥Öª¢¸ÓÃıN¦¨¬°FDA¦b¹L¥h15¦~¤¤§åãªvÀø¹L±Ó©Ê¥Öª¢¡]Àã¯l¡^ªººÓ·s¤À¤l¹êÅé¡A¦~¾P°â®pȹwp±N¶W¹L20»õ¬ü¤¸¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/5 ¤W¤È 08:45:34
²Ä 566 ½g¦^À³
|
¥²³Ó¤j:ÂX¤j¾AÀ³¯g¬O«Ü¦n ¦ý¤@ª½¥¼¬Ý¨ì:®ð³Ý:³o¤@¶ô ¬O¤ñ¸ûÅý¤H¥¢±æªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/5 ¤W¤È 08:02:03
²Ä 565 ½g¦^À³
|
FB825¦b¦~©³«e·|´£¥X°w¹ï¨u¨£¯e¯f°ª§K¬Ì²y³J¥ÕE¯gÔ¸s©t¨àÃÄ¥Ó½Ð, FDA¤U³]ªº©t¨àÃĬãµo¿ì¤½«ÇOOPD¦b¨ü²z«áªº90¤é¤º¹ï¨ä¶i¦æ¼f®Ö..., ©Ò¥H¦b2018.3.31¤é«e¥iª¾¹D©t¨àÃĸê®æ³q¹L§_? Àò±o©t¨àÃĸê®æ¤£Ãø!«ÂI¬OÃĪ«¯à§_³q¹LÁ{§É¹êÅç³Q§åã¤W¥«¤~¬OÃöÁä.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/7/4 ¤W¤È 10:31:41
²Ä 564 ½g¦^À³
|
¾Ö¤j Á{§É¹êÅç¥L̪º¥Î»y¤À²Ä¤@¦ì¨ü¸ÕªÌ¦¬®×©M³Ì«á¤@¦ì¨ü¸ÕªÌ¦¬®× ¡A³£¥s¦¬®×¡AFB825¤G´Á¦ü¥GnÂX¤j¾AÀ³¯g¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/3 ¤W¤È 08:53:40
²Ä 563 ½g¦^À³
|
½èºÃ¬Ý»´¬u²±Àù¯g·F²ÓM°ö¾i¡B²ÓM·sÃÄ¿z¿ï¥¥x»ùÈ???
¿W®a¸~½F·F²ÓM¤§§Ú¨£¡X±M³X¿úµ{±Ð±Â 2016-04-18 ¥Ñ ¥Íª«¨¦ µoªí¤_ ¬ì¾Ç https://kknews.cc/zh-tw/science/4qog3v.html ... ¥Íª«¨¦¡G®Ú¾Ú¥Ø«eªº¬ÛÃö¬ã¨s¨Ó¬Ý¡A¸~½F·F²ÓMªº¬ã¨s±Á{µÛþ¨Ç§xÃø¡H ¦^µª¡G¸~½F·F²ÓM¤ñ¨Ò§C¬O¸~½F·F²ÓM¬ã¨sªº¤@¤j§xÃø.......¥t¤@¤j§xÃø¡A±q¯f¤HÅ餺¤ÀÂ÷Àò¨úªº¤Ö¶q¸~½F·F²ÓM¡A¯Ê¥¢¦³®ÄªºÅé¥~°ö¾i¤èªk...µ¹¶i¤@¨B¬ã¨s±a¨Ó¤F·¥¤j§xÃø¡C¦b¦¹°ò¦¤Wªº¹v¦V¸~½F·F²ÓMªºÃĪ«¿z¿ï¤]¦s¦b§xÃø¡C¦]¦¹¡A¦³®Äªº±q¯f¤H¸~½F²Õ´¤¤Àò±o¸~½F·F²ÓM©M«Ø¥ß¸~½F·F²ÓMéwªº°ö¾iÅé¨t¡A¬O¥»»â°ì»Ýn¸Ñ¨MªºÃöÁä¬ì¾Ç°ÝÃD¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/2 ¤U¤È 08:43:39
²Ä 562 ½g¦^À³
|
¬u²±SNSO1·sÃľ֦³¥þ²y¿W¨B±M§Q¤§¸~½F·F²ÓM°ö¾i¡B¸~½F·F²ÓM·sÃÄ¿z¿ï¥¥x»ùȸӬO¦h¤Ö???
¥h¦~2016.4¤ëAbbVie¬°¦óÄ@·N¯{¤U¹dÃB¤Ñ»ù102»õ¬ü¤¸¦¬Áʬü°ê¸~½F·F²ÓM¤½¥qStemcentrx©ãª`Àù¯g·F²ÓM???
1.¸~½F·F²ÓM³Qµo²{¡IÀù¯g¬É¸ë§B´µªº»¨½ä¤Ñ¥¶É±×¤F¡I http://www.sohu.com/a/120797701_483678 ...¨ä竞争对¤âOncoMed¨î药¤½¥q说¡G¡§¦pªG¥L们ªº临§É试验¯à¨ú±o¦¨¥\ªº话¡A将会±o¨ì¤j«¬药¥ø50亿¬ü¤¸ªº额¥~§ë资¡C¡¨
2. 2016.11.2 Nature¡Gªv疗实Ê^½F¦³¤F©úÚ̹v标¡A肿½F¤z细MÚÌ实¦s¦b http://m.biodiscover.com/news/research/444029.html ...该¬ã¨s¤u§@¦³¤O¦a¤ä«ù¤F肿½F¤z细M¬O肿½F¼W长ªº¥Dn来·½¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/7/2 ¤W¤È 09:24:55
²Ä 561 ½g¦^À³
|
¦¬®×¬O³oÓ·N«ä¼Ú §Ú̳£»~·|¤F ¥u¦nÄ~Äòµ¥«Ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/7/1 ¤U¤È 09:49:11
²Ä 560 ½g¦^À³
|
³o»ò»¡¨ÓFB825¤µ¦~¤C¤ë¤~n¶}©l²Ä¤@¦ì¨ü¸ÕªÌ¦¬®×¡A ¤]´N¬O¦¬²Ä¤@¦ì¯f¤H¤§·N¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/7/1 ¤W¤È 09:18:59
²Ä 559 ½g¦^À³
|
²´·úªi¨à«G!!! AbbVie¾ú¥v¤Ñ»ù(102»õ¬ü¤¸) ¦¬Áʬü°ê¸~½F·F²ÓM¤½¥q Stemcentrx©ãª`Àù¯g·F²ÓM¡I¥Íª«§Þ³N¡u¿W¨¤Ã~¡v¤½¥q¹s¦¬¤J https://read01.com/xokN.html
¬u²±SNSO1·sÃÄ¿W¨B¥þ²y¤§¸~½F·F²ÓM°ö¾i¡B·sÃÄ¿z¿ï¥¥x(2019 US IND) 1.¥x¤j»â¥ý¥þ²yÅé¥~°ö¾iªÍÀù·F²ÓM ¦³§U·sÃĬãµo http://technews.tw/2014/03/26/ntu_co_culture_system_for_cancer_stem_cell/ 2.¦¨ªGµoªí¼v¤ù: https://www.youtube.com/watch?v=GyZRMvmHW_g
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/7/1 ¤W¤È 07:14:58
²Ä 558 ½g¦^À³
|
¤½¥q¨S¦^À³¿ù¡A¥L»¡ªº¦¬®×¬O¶}©l¦¬¯f¤H¡A§¹¦¨¦¬®×¬O«ü¦¬¨ì¹w´Á¼Æ¶qªº¯f¤H¡A¦¬®×¨Ã«Dµ²®×ªº·N«ä¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/30 ¤U¤È 11:13:38
²Ä 557 ½g¦^À³
|
³o©M¤½¥q«Å¶Ç¤Î¾Ö¤j¸ß°Ý¤½¥qªº¦^À³¦³¥X¤J §Ú°g±¦¤F
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/6/30 ¤U¤È 10:28:50
²Ä 556 ½g¦^À³
|
ªÑªF·|¦³»¡¡A7¤ë¶}©l¦¬²§¦ì©Ê¥Ö½§ª¢¯f¤H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/30 ¤U¤È 10:21:27
²Ä 555 ½g¦^À³
|
½Ðª`·N¾AÀ³¯g¤£¦P³á 2a¬O²§¦ì©Ê¥Ö½§ª¢ ²{¦b»¡ªº¬O°ª§K¬Ì²y³J¥ÕE¯gÔ¸s |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/6/30 ¤U¤È 10:17:52
²Ä 554 ½g¦^À³
|
ªÑªF·|¦³»¡¡A7¤ë¶}©l¦¬¯f¤H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/30 ¤U¤È 09:52:42
²Ä 553 ½g¦^À³
|
¤µ¦~²Ä¤T©un¥Ó½Ð·s¾AÀ³¯g°ª§K¬Ì²y³J¥ÕE¯gÔ¸s¡H ¨º²§¦ì©Ê¥Ö½§ª¢2aªº¶i«×¬°¦ó¡H ¹ê¦b¬Ý¤£À´¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/6/30 ¤U¤È 09:32:59
²Ä 552 ½g¦^À³
|
mops.twse.com.tw/nas/STR/415920170630M001.pdf
¥X²{¨âÓ·sªº¶i«×? FB825¡A2017n¥Ó½Ð©t¨àÃÄ»{©w FB704A¡A2017Q3¥Ó½ÐUS IND |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GFLYER10133103 |
µoªí®É¶¡:2017/6/27 ¤W¤È 11:13:58
²Ä 551 ½g¦^À³
|
¾ÖÅ@ªÌ¤j»¡±o¬O!¤j®a¤@°_@¤ß¤U¥hºÊ·þ¤½¥q...§Æ±æ¤½¥q¤£n¦A©ñ¦Ï¤U¥h¤F!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/6/27 ¤W¤È 10:34:26
²Ä 550 ½g¦^À³
|
¤@¤Á¦¨±Ñ½×^¶¯,ªÑ»ù¤]½T¹ê·|»¡¸Ü »ù®æª½ª½¸¨, ©Î³\¤jªÑªF¬°¤Fµ|½á ©Î³\¦³¤Hn¦Y³f ©Î³\2´Á¼Æ¾Ú¤£¦n¦³¤Hn¥X³f ©Î³\¨S¦³¥~³ò¥D¤O¦b¸ÌÀY Á`¤§,¤j®a³£³o»ò§V¤O¦¬¶°¸ê®Æ ¤j®a³£¦b¦P±ø²î¤W À³¸Ó¨S¤H§Æ±æ¥¦·|¨H²î§a ¤@°_§V¤O§a,¤ô¤âÌ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/27 ¤W¤È 09:41:33
²Ä 549 ½g¦^À³
|
·sÃľ֦³°ªÃBñ¬ùª÷(>5000¸U¬ü¤¸)+°ªÃB±ÂÅvª÷,Á{§É¦¨¥\¤W¥«¾P°â¤~¨ã¦³¦¨¬°«½SÃĪ«(¦~¾P°â>10»õ¬ü¤¸)ªº¼ç¤O!!!
ªü´µ§Q±d±N2´Ú¥Ö½§¯f¸ê²£§@»ù10»õ¥X°âµ¹LEO Pharma(+1.15»õ¬ü¤¸ªº¹w¥I´Ú=Á`»ù11.15»õ¬ü¤¸) https://read01.com/86oKOQ.html §Q¶ø¤½¥q±N¤ä¥I¤@µ§1.15»õ¬ü¤¸ªº¹w¥I´Ú¡AÀò±otralokinumab¥Î©ó¯SÀ³©Ê¥Öª¢¡]§YÀã¯l¡^¤Î¥ô¦ó¥¼¨ÓªºÃB¥~¥Ö½§¯f¾AÀ³¯gªº¥þ²y¿W®aÅv§Q¡Cªü´µ§Q±d«h«O¯dtralokinumabªvÀø©I§l¨t²Î¯e¯f¥H¤Î¥Ö½§¯f¥H¥~ªº¨ä¥L¾AÀ³¯gªº¥þ³¡Åv§Q¡C°£¤F¹w¥I´Ú¥~¡A§Q¶ø¤½¥qÁÙ±N¤ä¥Iªü´µ§Q±d°ª¹F10»õ¬ü¤¸ªº°Ó·~¤Æ¨½µ{¸Oª÷¤Î²£«~¥¼¨Ó¾P°âªº¯S³\Åv¨Ï¥Î¶O
PS:2017¦~ªü´µ§Q±d·s«¬ý³ÝÃĪ«tralokinumabºÓÃöÁä©ÊIII´ÁÁ{§É¬ã¨s¥¢±Ñ! ¥Î©ó¯SÀ³©Ê¥Öª¢¡]§YÀã¯l¡^P3Á{§É©Û¶Ò¤¤ : https://clinicaltrials.gov/ct2/show/NCT03131648
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/27 ¤W¤È 07:45:47
²Ä 548 ½g¦^À³
|
¾j¦ºÁx¤pªÌ?¼µ¦ºÁx¤jªÌ? ZiarcoªºZPL389¦bP2aÁ{§É¤½¥¬«á³Q¿ÕµØ¥H10»õ¬ü¤¸¦¬ÁÊ¡C ¥t¥~Dupilumab(Th2 polarization) Á{§É½w¸Ñ²v40%,¹w¦ô¾P°âÃB±NÀ½¤J¥@¬É³ÌºZ¾PÃĪ«µPº]²Ä17¦W! ·Q·QÁÙ¦³¶W¹L¤@¥bÅ妺¤Hªº60%¥«³õ!!! µ¥Á{§Éµ²ªG¤½¥¬¦b¨M©w?°O±o¿³ÂdµLº¦¶^´T¨î! ¦]¦¹«¥¤£»{¦Pc¤j©Ò¨¥·í¤µªÑ»ù¤£È¤@³Õ.
¤@. Dupilumab(Th2 polarization) Á{§É½w¸Ñ²v40% 1. http://www.diamondcapital.com.tw/news_detail.php?nwno=122 ¡K¨Ï¥ÎdupliumabªvÀøªº²Õ§O¬Û¸û©ó¦w¼¢¾¯²Õ¡A¥Íª«»s¾¯ªº¨Ï¥ÎÁö¯à±a¨Ó½w¸Ñ²vªº©úÅã´£¤É¡A¤£¹L¤´µM¥¼¶W¹L40% 2.临§É±¡况http://www.siqiquan.org/Home/ArticleDetail/721 2016¦~6¤ë¤½¥¬ªºIII´Á临§É试验数Õuªí©ú¡A试验组(dupilumab 300mg/1-2©P+TCS)¤¤39%ªº±wªÌ¥Öª¢¯g状获±o§¹¥þ®ø°h©ÎªÌ ³¡¤À®ø°h¡A¦Ó对·Ó组(TCS)¤¤仅¦³12%ªº±wªÌ获±o¦Pµ¥®ÄªG¡A达¨ì¤F临§É试验ªº¥Dn终点¡C
¤G.FB825(total Ige)Á{§É½w¸Ñ²v?????? 1.¤é¥»2013¦~ https://www.ncbi.nlm.nih.gov/pubmed/23883601 Total IgE at 6 months predicts remittance or persistence of atopic dermatitis at 14 months. 2.¼w°ê2009¦~Total Serum IgE as a Parameter to Differentiate Between Intrinsic and Extrinsic Atopic Dermatitis in Children https://www.medicaljournals.se/acta/content/html/10.2340/00015555-0627 ¡KSixty-three percent of patients were asIgE positive, while 37% did not reveal such IgE antibodies (PS:³o ²Õ¼Æ¾Ú»áȱoª±¨ý!) 3. Allergology International. 2014¦~ http://www.allergologyinternational.com/article/S1323-8930(15)30056-3/pdf ¡K. In AD patients, there was a strong correlation between total serum IgE levels and the positivity for a topic sensitization (R = 0.54, P < 0.0001; Spearman¡¦s rank correlation coefficient).
PS:³o²Õ¼Æ¾Ú»áȱoª±¨ý! 2016¦~12¤ëÁú°ê¤@½g5000¦WAD±wªÌªº¼Æ¾Ú¤ÀªR: Clinical Diversity of Atopic Dermatitis: A Review of 5,000 Patients at a Single Institute https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266112/ ¡K..AD may be classified into 2 different types, extrinsic and intrinsic, which are also called allergic and non-allergic types. The intrinsic type, or non-allergic type, shows normal IgE levels in addition to the absence of any sensitization to allergens, whereas the extrinsic or allergic type has increased specific IgE levels with sensitization to specific allergens.13,26 Of patients with AD, 76.3% were found to havethe extrinsic types,whereas the rest (23.7%) had the intrinsic type.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/6/26 ¤U¤È 10:37:27
²Ä 547 ½g¦^À³
|
¥»¤å±q2014/06/30µoªí¦Ü¤µ¡AªÑ»ùª½ª½¸¨¡A ¤¤¶¡¦³µL§j¼N¡AªÑ»ù·|»¡¸Ü§a¡A ªº½T¥Í§Þ»sÃĦ³¨ä¾Ç°Ý¡A ¨S¦³¥J²Ó¬ã¨s¡A¨ü¶Ëªº¥u¬O¦Û¤v¡C
¥H²{¦bªºªÑ»ù¨Ó¬Ý¤]³\¬Û¹ï¤£¦MÀI¡A ¨ü¶Ëªº¾÷·|¸û¤p¡A²¦³ºÁÙ¦³¤G´Án§¹¦¨¡A µ¥¦³¦nµ²ªG¦A¶i³õ¤£¬O¬Û¹ï¦w¥þ¶Ü?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/26 ¤U¤È 10:03:22
²Ä 546 ½g¦^À³
|
¹L±Ó©Ê¯e¯fP¯f¾÷Âà¬O§_§¹¥þ»P§K¬Ì²y³J¥ÕE¦Ê¤À¤§¦Ê¦³ÃöÁp ±qcscs¤j´£¨Ñªº¸ê®ÆÅã¥Ü§K¬Ì²y³J¥ÕE°§C¤£¥Nªí¯àµ´¹ï§ïµ½Á{§É¤Wªº¯f¼x ÁöµM¤£¯à¦]¦¹§YÂ_¨¥FB825¤]¦³¬Û¦Pªº©R¹B ¤£¹L¥Í§Þ¹ê¦b¤Ó±M·~¤F ¥~¦æ¤H¶i¨Ó±Çª÷¯uªº¥u¬O¾a¹B®ð µ¥¤F¸Ñ¬O«ç»ò¤@¦^¨Æ®É¤w¸gú¤F¤jµ§¾Ç¶O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/26 ¤U¤È 09:14:10
²Ä 545 ½g¦^À³
|
FB825ªº¶i«×°ÝÃD ¦pªG¬Ý¬u²±ºô¯¸¡A¤G´ÁÁÙ¨S¶}©l ¦pªG¬Ý¤¤¤Ñºô¯¸¡A¤w¶i¦æ¤G´Á ¬u²±ºô¯¸·íªì¤@´Á¹LÃö¡A¶i«×¤]¥u¬OÅã¥Ü¦bIND ¦]¦¹¾Ö¤jª½±µ°Ý¤½¥q¡A¤½¥qªí¥Ü§Y±N¦¬®×¡A§Ú·QÀ³¸Ó¬OÁ{§É¹êÅç§Y±N§¹¦¨¤§·N
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¨g10141690 |
µoªí®É¶¡:2017/6/26 ¤U¤È 03:55:20
²Ä 544 ½g¦^À³
|
¶RªÑ²¼´N¬O³o¼Ë¡A¶R¿ù¤F¡A´NÀË°Q¡A¤£¦æ´N²M¤@²M¤U¤@Ó·|§ó¦n¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¨g10141690 |
µoªí®É¶¡:2017/6/26 ¤U¤È 03:47:49
²Ä 543 ½g¦^À³
|
¤§«e¤@´ÁÁÙ¥¼¥X¨Ó´N¦³¤H»¡¤½¥q¥X°ÝÃD¤£·|¹L¡A¤@´Á¥X¨Ó¤F¼Æ¾Ú¤£¿ù´N»¡¤G´Á«Ü¦MÀI¡A²{¦b´Nºâ¤G´Á¥X¨Ó¤FªÖ©wÁÙ·|¦³¤H»¡¤T´Á¤£·|¹L¡A¤H¤§±`±¡¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/6/26 ¤U¤È 03:35:31
²Ä 542 ½g¦^À³
|
¤j®a´N@¤ßµ¥«Ý, ¤½¥q¬O§_¦A«×¥GÃl§ë¸ê¤H À³¸Ó«Ü§Ö´Nª¾¹D¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/6/26 ¤U¤È 03:29:34
²Ä 541 ½g¦^À³
|
¾Ö¤j´£¨ìªº¦¬®×¡A§Ú·Q¤½¥q¬O«ü¶}©l¦¬¯f¤H¡A¨Ã¤£¬Oµ²®×ªº·N«ä³á¡C
¥H¤U¬O§ÚÓ¤H¤Û·Qªº±À½× Y¤C¤ë¶}©l¦¬¯f¤H¡A¤E¤ë©³À³¸Ó·|¦³¼Æ¦r¥X¨Ó¡AY¼Æ¾Úº}«G¡A³Ì±ß¤µ¦~©³´N·|¨M©w±ÂÅv¹ï¶H¡]·íµM¤]¦³¥i¯à¤£µ¥¼Æ¾Ú¥X¨Ó´N§¹¦¨Ã±¬ù¡^
®³¨ì±ÂÅvª÷«á¡A´N¥i¥H¥Ó½Ð¤W¥«Âd¡A¶¶§Qªº¸Ü¡AÀ³¸Ó¬O©ú¦~6¤ë«e¡Aªk¤H¦b¿³Âd¦ü¥G¤£¯à¶R¡A¤@¥¹¤W¥«¡A¥unÀò±oªk¤H»{¦P¡]¼¯®ÚÀ³¸Ó·|«Ü¦³¿³½ì¡H¬Ý¨ì¤£¤Ö¸ê®Æ³£¸ò¥L¦³Ãö¡^¡AªÑ»ù´N·|±o¨ìÀ³¦³ªº¦ì¸m¡C
©Ò¥H¡A§Y¨Ï²{¦b¥D¤O¤£·ÓÅU¡A¤@¦~«á¶¶§Q¤W¥«Âd¡A¤]·|¦³ªk¤Hµ¹¤©¦X²zªºµû»ù¡A¨ì®ÉÔ¡A§Ú̦A¨Ó¬Ý¬Ý¡A¬u²±ªºªÑ»ù¨ì©³È¦h¤Ö¡ã |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¶Â½Þ10140151 |
µoªí®É¶¡:2017/6/26 ¤U¤È 03:05:42
²Ä 540 ½g¦^À³
|
§Úı±o¤µ¦~ªºªÑªF·|¡A°ß¤@ªº«ÂI¬O¡A¬ãµoªø»¡¡G§Ú¬Û«Hªø´Á«ù¦³¬u²±¡A±N·|¦³¹dÃBªº¦^³ø¡ã
¥Ø«e¢Ô¢Ð825°£¤F¶i«×¦³©µ¿ð¡A¨S¦³¨ä¥Lªº¨SÃa®ø®§¡A·Ó²z»¡¤½¥q»ùȬO©¹¤W´£¤É¡A¦ýµL©`ªº¬OªÑ»ù«ùÄò¯}©³¡C
ªñ¤@Ӥ릳¤H«ùÄò¥X²æªÑ²¼¡A«e¤T¦W¨÷°Ó¬O¡G¤¸¤j-ÃÀ¤å2154±i¡A¸s¯qª÷¹©-À]«e990±i¡A¤¸´I-ªQ¼w235±i¡C ¦³½ìªº¬O¶R¶W²Ä¤@¦W¬O¥ÃÂת÷-¥ú´_755±i¡A¦ý¬O¥L¬O½æ¶W¤¤¤Ñ809±i¡C¤]´N¬O»¡¤¤¤Ñ¤º³¡¦³¥X¨Ó±µ¡A¦ý¬O±µªº¤Ó¤Ö¤F¡C
¬u²±¤@ª½¯}©³¡A¨Ã«D¤½¥q«e´º¤£¦n¡A³æ¯Â¥u¬O¨S¦³¥D¤O·ÓÅU¡A¤½¥q¤]¤£·QºûÅ@ªÑ»ù¡A³s·s»D³£¬O¦³¤@·f¨S¤@·f¡A§Y¨Ï²{¦bªÑ»ùÄY«°¾Â÷À³¦³»ùÈ¡A¥D¤O¤]¤£·|·Q¦¹®É¶i³õ¡A¦]¬°¨S¦³·s»D¥i¥Hª£§@¡A³y¦¨´c©Ê´`Àô¡A«ùÄò¯}©³¡C
©Ò¥H¡AY·Q¦b¬u²±ÁȨì¿ú¡A¥u¯à¤ñ®ðªø¡A¥un¦³Ãį঳º}«G¼Æ¾Ú¡]¤£¥u¢Ô¢Ð825)¡AÁ`¦³¤@¤Ñ·|±ÂÅv¡AÁ`¦³¤@¤Ñ·|®³¨ìÃÄÃÒ¡A16ªº¼Æ¦r¡A¥¼¨Ó¥u¬OªÑ»ùªº¹sÀY¡C
°µ¦n°]°È³W¹º¡A¸ò¥L¤ñ®ðªø§a¡ã¡]§O§Ñ¤F¡A¬u²±ÁÙ¦³¤£¤ÖÂà§ë¸êªº¤pª÷³J¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/26 ¤U¤È 12:37:39
²Ä 539 ½g¦^À³
|
FB825¬I¥´1°wtotal ige¤U°40~50%; ù¤óQuilizumab¬I¥´3°wtotal ige¤U°20~30%. ¥t¥~FB825¬I¥´«á,°ªIgeªÌ¤U°³t«×§ó§Ö! FB825:http://tw.fountainmab.com/ftp01/JPM_Presentation_Slides_Final_CH.pdf Quilizumab:http://stm.sciencemag.org/content/6/243/243ra85.full
<20¤¸ªº»ù¦ì¤£È±o§ë¸ê?¦Û¤vµû¶q!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/26 ¤U¤È 12:37:28
²Ä 538 ½g¦^À³
|
RocheªºQuilizumab(MEMP1972A)Allergic asthma; Allergic rhinitis; Urticaria Á{§É±wªÌ¯Ç¤J±ø¥ó¨ÃµL³]©wIge/ total Ige¿z¿ïÈ! P1:https://clinicaltrials.gov/ct2/show/NCT01160861 P2:https://clinicaltrials.gov/ct2/show/NCT01582503 P2:https://clinicaltrials.gov/ct2/show/NCT01196039
¬u²±FB825²§¦ì©Ê¥Ö½§ª¢±wªÌÁ{§É±wªÌ: TFDA:https://www1.cde.org.tw/ct_taiwan/search_case2.php ¥Dn¯Ç¤J/±Æ°£±ø¥ó Y±z²Å¦X¥H¤U©Ò¦³±ø¥ó¡A¥i¥H°Ñ¥[¥»¸ÕÅç¡G 2. Âå®v¨Ì¾ÚHannifin & Rajka¶EÂ_¼Ð·Ç§P©w¬°²§¦ì©Ê¥Ö½§ª¢¡A¥B©ó¿z¿ï´Á¶¡½T»{¨ã¦³¹L±Óì±M¤@©ÊIgE¡C .... 6. Á`IgE¶q¡Ù 1500 IU/mL¡A¥B¨ä¤¤¦Ü¤Ö¦³¨â¶µ°w¹ïÀô¹Ò¹L±Ó줧±M¤@©ÊIgEªº¶q»Ý¡Ù 0.70 kU/L©Î¬O©óprick test¤¤§e¶§©Ê¤ÏÀ³¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥~¦æ¤H10135615 |
µoªí®É¶¡:2017/6/23 ¤U¤È 04:02:39
²Ä 537 ½g¦^À³
|
«ÜªÖ©w¡AªÑ»ù¨è·NÀ£§C¥Dn¬O¨ó©M¤jªÑªFÁ×µ|¡A¥i¯àÁٻݤ@¬q®É¶¡¡F²q±o¤£¿ùªºµe³o¸Ì´N¬O¨ó©M¤jªÑªF¦¨¥»°Ï ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/23 ¤W¤È 11:43:42
²Ä 536 ½g¦^À³
|
¨â®aº¥¦æº¥»·,¥á¥XÄw½X¨Ó¦Û³o®a¥i¯à©Ê³Ì¤j?
¼í®õ¥þªí¥Ü¡A¥Dn¨ü¨ìÂà§ë¸ê«n¤sn´£¦C¥¼¹ê²{·l¥¢¡A¥t¥~Âà§ë¸êªº¯E¹©¡B¤¤¸Îµ¥¥Í§ÞªÑªÑ»ù¤U¶^¡A¥H¤Î°ªøʹs°âªº¤H¥Á¹ô¶×·lµ¥¡A¨Ï±o¼í®õ¥þ±b¤W¥X²{¥¼¹ê²{¸ê²£´î·l¡A¶·´£¦C¯S§O¬Õ¾l¤½¿n¡A¾ÉPµLªk°t®§¡C ¡i«n¤s¦a¹p¡j³o®a¤½¥qÀò§Q²v¥´±Ñ¤j¥ß¥ú ³ºµo¤£¥XªÑ§Q https://tw.news.yahoo.com/%E5%8D%97%E5%B1%B1%E5%9C%B0%E9%9B%B7-%E9%80%99%E5%AE%B6%E5%85%AC%E5%8F%B8%E7%8D%B2%E5%88%A9%E7%8E%87%E6%89%93%E6%95%97%E5%A4%A7%E7%AB%8B%E5%85%89-%E7%AB%9F%E7%99%BC%E4%B8%8D%E5%87%BA%E8%82%A1%E5%88%A9-204600887.html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/23 ¤W¤È 10:52:15
²Ä 535 ½g¦^À³
|
¤@¶µì¥»³Q½÷·çµL´ÁÀÁ¸mªº·Ã¯lÃĪ«¡AÂà¤Æ¦¨¿ÕµØ¡]NVS¡^¥H10»õ¬ü¤¸¦¬Áʪº¬ÃÄ_¡C http://www.genetinfo.com/investment/featured/item/6393.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/23 ¤W¤È 10:50:10
²Ä 534 ½g¦^À³
|
FB825ªº»ùÈÁô¬ùÂæb³o½g! 湿¯l领°ì¡G·s«½S药¦a带 http://www.yyjjb.com/html/2016-12/30/content_245982.htm
¤½¥q¬£»¡5»õ¬ü¤¸¤§¤W¦ó¨Ó§j¼N??? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/6/23 ¤W¤È 10:47:33
²Ä 533 ½g¦^À³
|
¨Ã¤£¬O»¡³o¨Ç¾÷ºc¦b§j¼NDupilumab¡A ®Öã¤W¥«ªºÃĤw³QÃÒ¹ê¹L¡A¦Ó¤£¬O¾ÌªÅ·Q¹³¡C Å餺IgE¤£¬O¯S§O°ªªº·|¥ÎXolair¡A¹L°ªªº³¡¤À¤~¬OQuilizumab»PFB825³]©wªº±Ú¸s¡A ³o¨Ç¥Ö½§¬ÛÃöªº¯e¯f¸òIgE¦³Ãö¨S¿ù¡A¦ý¤]¤£¬O§¹¥þ³£IgE³y¦¨ªº¡A ¨Ï¥Î«áIgE·|¤U°¨S¿ù¡A¤]n¦³Á{§É¯f¼xªº§ïµ½¤~¦³¥Î¡A Á{§É¤G´Á³£ÁÙ¨S°µ¡A²{¶¥¬qn»¡FB825¯à½æ¨ì´X¤Q»õ¬üª÷? ¦pªG¸êª÷¥R¨¬¡A¤Ï¥¿²{¦b¤~¤Q´X¶ô¡AºÉ¶q¶R¡A¦³¹Ú³Ì¬ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/23 ¤W¤È 10:34:36
²Ä 532 ½g¦^À³
|
³o¨Ç°ê¥~±M·~§ë¸ê¾÷ºc¤@°_§j¼Nº]º¬O¥Î¤_¤¤««×过±Ó©Ê¥Ö肤ª¢ªºDupilumab?
1.¨C¦~¡AEP Vantage 会进¦æ«e20ªº¤p¤À¤l©M¥Íª«¨î剂统计¤ÀªR¡A®ÚÕu预¦ô5¦~内¥«场销°â潜¤O进¦æ±Æ¦W¡C¦¹¦¸Evaluate¡¦s top 20±Æ¦W¤¤¦³15个药ª«¥i¯à会¦¨为«½S¬µ弹¡C http://www.bioon.com/3g/id/6697964/
2.湿¯l领°ì¡G·s«½S药¦a带 http://www.yyjjb.com/html/2016-12/30/content_245982.htm
3.¡uÃÄ«~¬G¨Æ¡v2017¡AÂåÃĦ¿´ò©M«½S¬µ¼u https://www.cnread.news/content/138439.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/6/23 ¤W¤È 10:02:21
²Ä 531 ½g¦^À³
|
Á{§Éµ²ªG¦n·íµMªÑ»ù·|¤Ï¬M¡A¦b¨S¦³½T¤Áµ²ªG¤§«enÁקK³Q§j¼Nªº®ø®§µ¹§l¤Þ¤F¡A ·íµM§Æ±æ¥xÆW¥Í§Þ¬É¯à¦³¯u¥¿¦nªºÃĤW¥«¡A ¹L«×¾Þ§@¡A¸Ø¤j¡A¬Æ¦Ü¥u¬Oª£§@¦Ó¨S¦³¯u§÷¹ê®Æ¡A ³Ì«á¨ü¶Ëªº³£¬O´²¤á§ë¸ê¤H¡A§ó¥i¯à³y¦¨¥Í§ÞÃþªÑªº§C°g¡A ²z©Ê§PÂ_¡A«OÅ@¦Û¤v¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GFLYER10133103 |
µoªí®É¶¡:2017/6/22 ¤U¤È 11:09:27
²Ä 530 ½g¦^À³
|
±À´ú¬O¦X¨Ö¨ó©M¸Ì¨º¨Ç¤j©@ªº§Þ³N¬ã¨s°ª¶¥¥DºÞ¡A³o¨Ç¤H¦³ªº¬OµLÀv§Þ³NªÑ©Î10¤¸»{ªÑªº¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/6/22 ¤U¤È 09:28:24
²Ä 529 ½g¦^À³
|
¬O°Ú,¤W¶g1000±i¥H¤W¤jªÑªF¥X³f1200¦h±i ¤µ¤Ñ¬Ý¼Ë¤l¥ç¥X³f¤£¤Ö »á¥O¤H¾á¤ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/22 ¤U¤È 09:09:01
²Ä 528 ½g¦^À³
|
¾Ö¤j Á{§É¼Æ¾Ú¤º¦æªº¤HÀ³¸Ó¤w¸g¥i¥H¸ÑŪ ¦³¤H¤@ª½¦bÅܲ{ ¹ê¦bÅý§Ú¦³¤@ºØ¤£²»ªº¹w·P |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/6/22 ¤U¤È 08:22:05
²Ä 527 ½g¦^À³
|
§Ú¤µ¤Ñ¤U¤È¥h°Ý¤½¥q©Ò±o¨ìªºµª®×¼Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/22 ¤U¤È 07:19:15
²Ä 526 ½g¦^À³
|
¾Ö¤j FB825²Ä¤G´Á2aªíq§¹¦¨¤é¬°¤µ¦~9¤ë1¤é À³¸Ó¬O±µªñ§¹¦¨n¦¬®×¤F¤~¹ï µ¥³oÓ¶iµ{ªºµ²ªG§a Y¬O¦¨¥\ªÑ»ù¥²¦³¤Ï¬Mªº
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/22 ¤U¤È 04:17:38
²Ä 525 ½g¦^À³
|
FDA¥h¦~12¤ë14¤é刚刚§åã辉·çªá费52亿¬ü¤¸¦¬购Anacor获±oªº¤p¤À¤l¯S应©Ê¥Öª¢药ª«Eucrisa¡]crisaborole¡A«DÍrÊ^PDE4§í¨î剂¡^¡A¬O15¦~来FDA§å㪺²Ä¤@个ªv疗¯S应©Ê¥Öª¢ªº·s¤À¤l实Ê^¡A销°â®pÈ预测¥i达20亿¬ü¤¸¡C
15¦~来FDA§å㪺²Ä¤@个ªv疗¯S应©Ê¥Öª¢ªº·s¤À¤l实Ê^Eucrisa¡]crisaborole¡A销°â®pÈ预测¥i达20亿¬ü¤¸ 15¦~来FDA§å㪺²Ä¤@个ªv疗¯S应©Ê¥Öª¢ªº§ÜÅé·sÃÄDupixent¡]dupilumab¡^销°â®pÈ预测¥i达40+亿¬ü¤¸ http://www.sohu.com/a/130830092_464396
¦p¦PFUN¤j»P¬ãµoªø©Ò»¡,FB825¯à¦¨¥\´Nµ´¹ï¬O«½SÃĪ«(¦~¾P°âÃB¶W¹L10»õ¬ü¤¸,¦Ó¦~¾P°âÃB¹F50»õ¬ü¤¸¬O¶W«½SÃĪ«!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/6/22 ¤U¤È 03:58:16
²Ä 524 ½g¦^À³
|
¥²³Ó¤j: ¤½¥q»¡FB825²Ä¤G´Áªº2a¤w¸gn¦¬®×¤F ¦pªG2a®ÄªG¨}¦n,´N¤£»Ý°µ2b¤F
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/22 ¤U¤È 03:46:20
²Ä 523 ½g¦^À³
|
FB825Á{§É¶µ¥Ø¬OÀã¯l,¤£¦b®ð³Ý/ëC³Â¯l/»óª¢±wªÌ! FB825¬I¥´1°wtotal ige¤U°40~50%; ù¤óQuilizumab¬I¥´3°wtotal ige¤U°20~30%.
2016¦~12¤ëÁú°ê¤@½g5000¦WAD±wªÌªº¼Æ¾Ú¤ÀªR: Clinical Diversity of Atopic Dermatitis: A Review of 5,000 Patients at a Single Institute https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266112/
............Our study also proved the correlation of serum IgE levels with the severity of AD, which is a meaningful result as a large number of patients were analyzed. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó10142431 |
µoªí®É¶¡:2017/6/22 ¤U¤È 03:21:12
²Ä 522 ½g¦^À³
|
ROGER¤jªí¹Fªº¬OQuilizumabÁ{§É¶µ¥Ø¬°¹L±Ó©Êý³Ý¡B¹L±Ó©Ê»óª¢ ¡BëC³Â¯l¡A¦ÓFB825Á{§É¶µ¥Ø¬°²§¦ì©Ê¥Ö½§ª¢¡A¾AÀ³¯g¤£¦P¡C cscs¤jªí¹Fªº¬OFB825¸òRocheªºQuilizumabÁö¬O§¹¥þ¤£¦PªF¦è¡A ¦ý¬O·|»{¦PӼЪº¡A¦]¦¹Quilizumab¤£Ä~ÄòÁ{§É¹êÅç¡AFB825®£¤£ ¼ÖÆ[¡C ¦U¦Û¦¨²z¡AºÝ¬ÝÆ[¹î¨¤«×¬°¦ó¡A¯uªº¥²¶·¤HÅé¹êÅç¤~ª¾µ²ªG¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gcscs10144679 |
µoªí®É¶¡:2017/6/22 ¤U¤È 01:58:55
²Ä 521 ½g¦^À³
|
www.ncbi.nlm.nih.gov/pmc/articles/PMC4797126/ A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma Conclusions Quilizumab had an acceptable safety profile and reduced serum IgE. However, targeting the IgE pathway via depletion of IgE-switched and memory B cells was not sufficient for a clinically meaningful benefit for adults with allergic asthma uncontrolled by standard therapy. ²³æ»¡´N¬O¹ï®ð³Ý¯f¤H¥i°§CIgE¦ý¨S¦³Á{§É¤W¦³·N¸qªºÀø®Ä¡C
www.sciencedirect.com/science/article/pii/S0091674916306315?via%3Dihub A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria
Although quilizumab reduced median serum IgE level approximately 30% in patients with CSU, it did not cause clinically meaningful improvements in the weekly ISS or the UAS7. ¹ïëC³Â¯l¯f¤HªºIgE¦³´î¤Ö30%¦ý¤]¨S¦³Á{§É¤W¯f¼x¦³·N¸qªº§ïµ½
¤@ÓÃĦb¥þ²yªº¾P°â¦ôȤ]¤£¬O§A¤@®a¤½¥q¯à¿W¦ûªº¡A³o¼Ëªººâªk¥u¬O¦b§j¡A °£«D§A¬O¿W¦û¡AÅã¦Ó©ö¨£¡A¬u²±¨Ã¤£¬O¿W¦û¡C anti-IL6¤]¬O³o¼Ë¡A¤£¬O»¡³oÃþ¾AÀ³¯gªº¥«³õ¦³³o»ò¤j¡A§A´N¯à¤À¨ì¡A aptamerªº¬Ýªk«O¦u¤@ÂI¡A¤£¬O¦¨¥»¤ñ¸û§C´N¦n¡A¦³®ÄªG¤~¬O«ÂI¡C §K¬ÌÀøªk¤£¬O¥Î»¡ªº´N°µ±o¥X¨Ó¡An±qªù¥~º~¸ó¨ì¤@Ó·s»â°ì¡A¦³¤°»ò¤ñ§O¤H±jªº§Þ³N©O? Biosimilar¬O¤ñ²£¶q¡A¤ñ»ù®æ¡A¥@¬É¤W«Ü¦h°ê®a³£¦b°µ¡A¬u²±¦³¯à¤O°µªº¤ñ§O¤H¤j¶Ü? ¤]³\¯àÁȨì¤@ÂI¿ú¡A¦ýBiosimilar¨S¤°»òÃzµo¤O¡A ¦U¦ìÁÙ¬O·Q²M·¡§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910144700 |
µoªí®É¶¡:2017/6/22 ¤U¤È 01:51:34
²Ä 520 ½g¦^À³
|
¤@ª¾¥b¸Ñ! QuilizumabÁ{§É¶µ¥Ø:Allergic asthma; Allergic rhinitis; Urticaria Á{§É¥´[3°w] totalIgeµ²ªG: http://stm.sciencemag.org/content/6/243/243ra85.full
FB825Á{§É¶µ¥Ø:Atopic dermatitis²§¦ì©Ê¥Ö½§ª¢=Àã¯l(¤£¬O°®Å~)FDA 3¤ë®Ö㪺Dupilumab¬OªvÀø²§¦ì©Ê¥Ö½§ª¢=Àã¯l) FB825 ¤@´ÁÁ{§É¥u¥´[1°w]totalIgeµ²ªG: http://tw.fountainmab.com/ftp01/JPM_Presentation_Slides_Final_CH.pdf
°ê¥~¤@°ï§ë¸ê¾÷ºc¤ÀªR³ø§iDupilumab销°â®pÈ¥i达$40亿+ªº«½S ¬Æ¦Ü¹F50»õ¬ü¤¸ 湿¯l·s药dupilumab获§å¡G©wɲ3.7ÉE¬ü¤¸/¦~http://www.sohu.com/a/130830092_464396
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¾ÖÅ@ªÌ10140685 |
µoªí®É¶¡:2017/6/22 ¤U¤È 01:30:13
²Ä 519 ½g¦^À³
|
|
¡@ |
¦^°Q½×°Ï1¶ |
³Ì·s100«h¦^ÂÐ >> |